Invivyd (IVVD) to Release Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $34.45 million for the quarter.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. The company had revenue of $13.80 million during the quarter, compared to analysts' expectations of $13.57 million. On average, analysts expect Invivyd to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Invivyd Stock Up 3.5 %

Shares of NASDAQ IVVD traded up $0.02 during trading on Friday, reaching $0.63. 680,359 shares of the stock were exchanged, compared to its average volume of 4,304,306. The company has a market capitalization of $75.38 million, a price-to-earnings ratio of -0.32 and a beta of 0.41. The business's 50-day moving average price is $0.70 and its 200 day moving average price is $0.77. Invivyd has a twelve month low of $0.35 and a twelve month high of $2.74.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on IVVD shares. D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Invivyd in a report on Wednesday, March 26th.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.